ClinicalTrials.Veeva

Menu
J

Jackson Heart Clinic | Jackson, MS

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

sodium
aspirin
Edoxaban
Milvexian
Inclisiran
Ziltivekimab
prasugrel
valsartan
cholesterol
Vitamin K

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 43 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling
Atrial Fibrillation
Stroke
Drug: Non-Vitamin K Oral Antagonists
Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Not yet enrolling
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Ziltivekimab
Drug: Placebo

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Rest...

Enrolling
Dilated Cardiomyopathy
Heart Failure With Reduced Ejection Fraction (HFrEF)
Device: AccuCinch Ventricular Restoration System
Drug: Guideline-Directed Medical Therapy

The purpose of the Diamond-AF II study is to establish the safety and effectiveness of the DiamondTemp Ablation System for the treatment of drug refr...

Active, not recruiting
Atrial Fibrillation
Persistent Atrial Fibrillation
Device: Radiofrequency Ablation

The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when c...

Enrolling
Cryptogenic Stroke
Patent Foramen Ovale
Device: FDA-approved PFO closure device
Device: Encore PFO closure device

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK...

Begins enrollment this month
Chronic Limb-Threatening Ischemia
Device: Esprit BTK System

The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everoli...

Active, not recruiting
Critical Limb Ischemia (CLI)
Device: Percutaneous Transluminal Angioplasty (PTA) Device
Device: Esprit BTK Device

The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisira...

Active, not recruiting
Acute Coronary Syndrome
Drug: Inclisiran

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Abbott logo
Medtronic logo
Novartis logo
ZOLL Medical logo
Duke University logo
S
A
Daiichi Sankyo logo
E
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems